Tilray Brands (TLRY) Gains from Investment Securities (2019 - 2025)
Tilray Brands' (TLRY) quarterly Gains from Investment Securities came in at -$15.0 million in Q3 2025, down 1600.0% on a QoQ basis from $1.0 million in Q2 2024.
Tilray Brands (TLRY) Gains from Investment Securities (2019 - 2025) Analysis & Trends
Tilray Brands (TLRY) has 7 years of Gains from Investment Securities data on file, last reported at -$15.0 million in Q3 2025.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$15.0 million in Q3 2025, while the trailing twelve-month figure through May 2026 was -$15.0 million (changed N/A YoY) and the FY2026 annual result came in at -$15.0 million, changed N/A from the prior year.
- Gains from Investment Securities eased to -$15.0 million in Q3 2025, from $1.0 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $1.0 million in Q2 2024 to a low of -$30.7 million in Q1 2022.
- A 5-year average of -$6.2 million and a median of $251500.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 5363.98% — and 2024, when it jumped 242.47%.
- Tracing TLRY's Gains from Investment Securities over 5 years: stood at $845000.0 in 2021, then sank by 75.03% to $211000.0 in 2022, then jumped by 42.18% to $300000.0 in 2023, then soared by 233.33% to $1.0 million in 2024, then sank by 1600.0% to -$15.0 million in 2025.
- The last three Gains from Investment Securities figures came in at -$15.0 million (Q3 2025), $1.0 million (Q2 2024), and -$6.0 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | -15.00 Mn |
| Aug 31, 2025 | -15.00 Mn |
| May 31, 2024 | 1.00 Mn |
| May 31, 2024 | 1.00 Mn |
| Feb 29, 2024 | -5.98 Mn |
| Feb 29, 2024 | -5.98 Mn |
| Nov 30, 2023 | 300,000.00 |
| Nov 30, 2023 | 300,000.00 |
| Aug 31, 2023 | -11.11 Mn |
| Aug 31, 2023 | -11.11 Mn |
| May 31, 2023 | 292,000.00 |
| May 31, 2023 | 292,000.00 |
| Feb 28, 2023 | 352,000.00 |
| Feb 28, 2023 | 352,000.00 |
| Aug 31, 2022 | 211,000.00 |
| Aug 31, 2022 | 211,000.00 |
| May 31, 2022 | -15.59 Mn |
| May 31, 2022 | -15.59 Mn |
| Feb 28, 2022 | -30.75 Mn |
| Feb 28, 2022 | -30.75 Mn |